Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study

Ítems similars

• Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study
  per: Cowan, Juthaporn, et al.
  Publicat: (2020)
• Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency
  per: Rojavin, Mikhail A., et al.
  Publicat: (2019)
• Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
  per: Hagan, John B., et al.
  Publicat: (2010)
• Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
  per: Kanegane, Hirokazu, et al.
  Publicat: (2014)
• Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study
  per: van Schaik, Ivo N., et al.
  Publicat: (2019)